This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The Brigham and Women's Hospital, Inc.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Ivan D Mascanfroni: Innovator in Autoimmune Disease Treatment
Introduction
Ivan D Mascanfroni is a notable inventor based in Brighton, MA (US). He has made significant contributions to the field of immunology, particularly in the treatment of autoimmune diseases. His innovative approaches have the potential to change the landscape of how these conditions are managed.
Latest Patents
Ivan D Mascanfroni holds 1 patent for his work titled "Methods and compositions of treating autoimmune diseases." This patent describes methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. Specifically, it details how an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL 27/ectonucleotidase CD39 axis signaling. The methods and compositions outlined in this patent can be utilized for treating autoimmune diseases or disorders, including multiple sclerosis (MS) and type 1 diabetes.
Career Highlights
Mascanfroni is affiliated with The Brigham and Women's Hospital, Inc., where he continues to advance research in immunology. His work is characterized by a commitment to understanding and addressing complex autoimmune conditions.
Collaborations
One of his notable collaborators is Francisco Javier Quintana. Their partnership exemplifies the collaborative spirit in scientific research, particularly in the pursuit of innovative treatments for autoimmune diseases.
Conclusion
Ivan D Mascanfroni's contributions to the field of autoimmune disease treatment through his innovative patent highlight his role as a leading inventor in this critical area of medical research. His work promises to pave the way for new therapeutic strategies that could significantly improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
